title: Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension.
abstract: OBJECTIVE
  Continuous i.v. epoprostenol (prostacyclin) therapy improves survival and quality of life in patients with pulmonary arterial hypertension (PAH). i.v. epoprostenol therapy may be limited by serious complications related to the need for an implanted central venous catheter, and its chemical instability and short half-life. Treprostinil is a longer-acting prostacyclin analog, chemically stable, and suitable for continuous subcutaneous administration. We report successful transitioning to subcutaneous treprostinil of patients who presented with life-threatening complications of i.v. epoprostenol delivery.
  
  
  METHODS
  Open, uncontrolled study.
  
  
  METHODS
  ICUs and departments of cardiology at academic hospitals.
  
  
  METHODS
  Eight patients with PAH treated with continuous i.v. epoprostenol.
  
  
  METHODS
  Transition to subcutaneous treprostinil following an empiric protocol.
  
  
  RESULTS
  Transition to treprostinil was achieved successfully in 21 to 96 h, with no major adverse side effects, and no change in the improved clinical status achieved with i.v. epoprostenol. Doses of epoprostenol before transition ranged from 3.5 to 75 ng/kg/min (mean, 27 ng/kg/min). Doses of treprostinil at completion of the transition ranged from 3 to 65 ng/kg/min (mean, 22 ng/kg/min). Four to 11 months later, the patients remained clinically improved. In spite of mild-to-moderate infusion site pain, all patients reported an improved sense of comfort and well-being.
  
  
  CONCLUSIONS
  Patients with PAH can be safely transitioned from treatment with i.v. epoprostenol to subcutaneous treprostinil.
authors: Department of Cardiology, Erasme University Hospital, Brussels, Belgium.
authors: Jean-Luc
authors: JL
authors: Vachiéry
authors: Nicholas
authors: N
authors: Hill
authors: Diane
authors: D
authors: Zwicke
authors: Robyn
authors: R
authors: Barst
authors: Shelmer
authors: S
authors: Blackburn
authors: Robert
authors: R
authors: Naeije
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D011464:Epoprostenol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology; D007260:Infusion Pumps; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged
chemical_list: D000959:Antihypertensive Agents; D011464:Epoprostenol